Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127103121 | 12710312 | 1 | I | 200912 | 20160823 | 20160902 | 20160902 | EXP | US-PFIZER INC-2016401919 | PFIZER | 59.00 | YR | M | Y | 0.00000 | 20160902 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127103121 | 12710312 | 1 | PS | DOXORUBICIN HCL | DOXORUBICIN HYDROCHLORIDE | 1 | UNK, CYCLIC | Y | 50467 | ||||||||||
| 127103121 | 12710312 | 2 | SS | DOXORUBICIN HCL | DOXORUBICIN HYDROCHLORIDE | 1 | UNK, CYCLIC | Y | 50467 | ||||||||||
| 127103121 | 12710312 | 3 | SS | CYTARABINE. | CYTARABINE | 1 | UNK, CYCLIC | Y | 71868 | ||||||||||
| 127103121 | 12710312 | 4 | SS | CYTARABINE. | CYTARABINE | 1 | UNK, CYCLIC | Y | 71868 | ||||||||||
| 127103121 | 12710312 | 5 | SS | VINCRISTINE SULFATE. | VINCRISTINE SULFATE | 1 | UNK, CYCLIC | Y | 71484 | ||||||||||
| 127103121 | 12710312 | 6 | SS | VINCRISTINE SULFATE. | VINCRISTINE SULFATE | 1 | UNK | Y | 71484 | ||||||||||
| 127103121 | 12710312 | 7 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | UNK, CYCLIC | Y | 0 | ||||||||||
| 127103121 | 12710312 | 8 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | UNK, CYCLIC | Y | 0 | ||||||||||
| 127103121 | 12710312 | 9 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | UNK, CYCLIC | Y | 0 | ||||||||||
| 127103121 | 12710312 | 10 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | UNK, CYCLIC | Y | 0 | ||||||||||
| 127103121 | 12710312 | 11 | SS | METHOTREXATE. | METHOTREXATE | 1 | UNK, CYCLIC | Y | 0 | ||||||||||
| 127103121 | 12710312 | 12 | SS | METHOTREXATE. | METHOTREXATE | 1 | UNK, CYCLIC | Y | 0 | ||||||||||
| 127103121 | 12710312 | 13 | C | DASATINIB | DASATINIB | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127103121 | 12710312 | 1 | Acute lymphocytic leukaemia |
| 127103121 | 12710312 | 3 | Acute lymphocytic leukaemia |
| 127103121 | 12710312 | 5 | Acute lymphocytic leukaemia |
| 127103121 | 12710312 | 7 | Acute lymphocytic leukaemia |
| 127103121 | 12710312 | 9 | Acute lymphocytic leukaemia |
| 127103121 | 12710312 | 11 | Acute lymphocytic leukaemia |
| 127103121 | 12710312 | 13 | Acute lymphocytic leukaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127103121 | 12710312 | HO |
| 127103121 | 12710312 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127103121 | 12710312 | Acute lymphocytic leukaemia | |
| 127103121 | 12710312 | Colitis | |
| 127103121 | 12710312 | Disease progression | |
| 127103121 | 12710312 | Epiploic appendagitis | |
| 127103121 | 12710312 | Neutropenic infection | |
| 127103121 | 12710312 | Rash | |
| 127103121 | 12710312 | Renal failure | |
| 127103121 | 12710312 | Sepsis | |
| 127103121 | 12710312 | Subdural haematoma |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127103121 | 12710312 | 2 | 20100105 | 0 | ||
| 127103121 | 12710312 | 4 | 20100105 | 0 | ||
| 127103121 | 12710312 | 6 | 20100105 | 0 | ||
| 127103121 | 12710312 | 8 | 20100105 | 0 | ||
| 127103121 | 12710312 | 10 | 20100105 | 0 | ||
| 127103121 | 12710312 | 12 | 20100105 | 0 |